Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

An Examination of Electronic Cigarette Content on Social Media: Analysis of E-Cigarette Flavor Content on Reddit
Wang, Lei , Leischow, Scott J. , Okamoto, Janet , Zhan, Yongcheng , Li, Qiudan , Zeng, Daniel Dajun

Mayo Clinic

International Journal of Environmental Research and Public Health | November 24, 2015 | Volume: 12 | Issue: 11 | Pages: 14916-14935

10.3390/ijerph121114916 | PMID 26610541 Get It

In recent years, the emerging electronic cigarette (e-cigarette) marketplace has shown great development prospects all over the world. Reddit, one of the most popular forums in the world, has a very large user group and thus great influence. This study aims to gain a systematic understanding of e-cigarette flavors based on data collected from Reddit. Flavor popularity, mixing, characteristics, trends, and brands are analyzed. Fruit flavors were mentioned the most (n = 15,720) among all the posts and were among the most popular flavors (n = 2902) used in mixed blends. Strawberry and vanilla flavors were the most popular for e-juice mixing. The number of posts discussing e-cigarette flavors has increased sharply since 2014. Mt. Baker Vapor and Hangen were the most popular brands discussed among users. Information posted on Reddit about e-cigarette flavors reflected consumers’ interest in a variety of flavors. Our findings suggest that Reddit could be used for data mining and analysis of e-cigarette-related content. Understanding how e-cigarette consumers’ view and utilize flavors within their vaping experience and how producers and marketers use social media to promote flavors and sell products could provide valuable information for regulatory decision-makers.
ASPP1/2-PP1 complexes are required for chromosome segregation and kinetochore-microtubule attachments
Zhang, Pingzhao , Zhang, Yuanyuan , Gao, Kun , Wang, Yuqi , Jin, Xiaofeng , Saiyin, Hexige , Wang, Dejie , Peng, Jintao , Ma, Jian , Tang, Yan , Wumaier, Reziya , Yu, Hongxiu , Dong, Yimin, Yu, Long , Wei, Youheng , Ma, Jian, Huang, Haojie , Wang, Chenji

Mayo Clinic

Oncotarget | November 22, 2015 | Volume: 6 | Issue: 39 | Pages: 41550-41565

10.18632/oncotarget.6355 | PMID 26595804 Get It

Interventions for dissociated vertical deviation
Wang, Xue , Holmes, Jonathan M. , Hatt, Sarah R. , Holmes, Jonathan M.

Mayo Clinic

Cochrane Database of Systematic Reviews | November 20, 2015 | Volume: 2016 | Issue: 1 | Pages: No page available

10.1002/14651858.cd010868.pub2 | PMID 26587695 Get It

Natural History, Complications and Re-Intervention Rates of Asymptomatic Residual Stone Fragments after Ureteroscopy: a Report from the EDGE Research Consortium
Brotherhood, Hilary, Sur, Roger L. , Wang, An Qi, Knudsen, Bodo E. , Yong, Courtney , Marien, Tracy , Miller, Nicole L. , Krambeck, Amy E. , Charchenko, Cameron, Humphreys, Mitchell R. , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | November 14, 2015 | Volume: 195 | Issue: 4 Part 1 | Pages: 982-986

10.1016/j.juro.2015.11.009 | PMID 26585680 Get It

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L. , Durham, Benjamin H. , Haroche, Julien , Yao, Zhan , Ma, Jing , Wang, Zhaoming , Choi, John , Kim, Eun Hee , Cohen‐Aubart, Fleur , Lee, Stanley Chun-Wei , Gao, Yijun , Micol, Jean‐Baptiste , Campbell, Patrick , Walsh, Michael P. , Sylvester, Brooke E., Dolgalev, Igor , Aminova, Olga, Heguy, Adriana , Zappile, Paul, Nakitandwe, Joy , Ganzel, Chezi , Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Lacouture, Mario E. , Gahl, William A. , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Briggs, Samuel, Fasan, Omotayo , Block, Jared , Héritier, Sébastien , Solit, David B. , Hyman, David M. , Baselga, José , Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rosen, Neal , Parikh, Sameer A. , Ross, Jeffrey S , Donadieu, Jean , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar , Diamond, Eli L , Wang, Zhaoming , Héritier, Sébastien , Durham, Benjamin

Mayo Clinic

Cancer Discovery | November 13, 2015 | Volume: 6 | Issue: 2 | Pages: 154-165

10.1158/2159-8290.cd-15-0913 | PMID 26566875 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAFV600E mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAFV600E–wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAFV600E–wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. Significance: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders. Cancer Discov; 6(2); 154–65. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis
Brown, Robert S., McMahon, Brian J. , Wong, John B. , Ahmed, Ahmed T. , Mouchli, Mohamed A., Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Lok, Anna S. , Wang, Zhen , Prokop, Larry J. , Murad, M Hassan

Mayo Clinic

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 319-333

10.1002/hep.28302 | PMID 26565396 Get It

Perinatal or mother‐to‐child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk factor for chronic HBV infection worldwide. In addition to hepatitis B immune globulin and vaccination, oral antiviral therapies in highly viremic mothers can further decrease MTCT of HBV. We conducted a systematic review and meta‐analysis to synthesize the evidence on the efficacy and maternal and fetal safety of antiviral therapy during pregnancy. A protocol was developed by the American Association for the Study of Liver Diseases guideline writing committee. We searched multiple databases for controlled studies that enrolled pregnant women with chronic HBV infection treated with antiviral therapy. Outcomes of interest were reduction of MTCT and adverse outcomes to mothers and newborns. Study selection and data extraction were done by pairs of independent reviewers. We included 26 studies that enrolled 3622 pregnant women. Antiviral therapy reduced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.4) or infant HBV DNA seropositivity (risk ratio = 0.3, 95% confidence interval 0.2‐0.5) at 6‐12 months. No significant differences were found in the congenital malformation rate, prematurity rate, and Apgar scores. Compared to control, lamivudine or telbivudine improved maternal HBV DNA suppression at delivery and during 4‐8 weeks' postpartum follow‐up. Tenofovir showed improvement in HBV DNA suppression at delivery. No significant differences were found in postpartum hemorrhage, cesarean section, and elevated creatinine kinase rates. Conclusions: Antiviral therapy improves HBV suppression and reduces MTCT in women with chronic HBV infection with high viral load compared to the use of hepatitis B immunoglobulin and vaccination alone; the use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnancy with no increased adverse maternal or fetal outcome. (Hepatology 2016;63:319–333)
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
McMahon, Brian J. , Brown, Robert S., Wong, John B. , Ahmed, Ahmed T. , Farah, Wigdan , Almasri, Jehad , Alahdab, Fares , Benkhadra, Khalid, Mouchli, Mohamed A., Singh, Siddharth , Mohamed, Essa A. , Dabrh, Abd Moain Abu , Murad, M. Hassan , Mohammed, Khaled , Abu Dabrh, Abd Moain, Murad, Mohammad Hassan, Lok, Anna S. , Prokop, Larry J. , Wang, Zhen , Murad, M Hassan , Abu Dabrh, Abd Moain , Farah, Wigdan , Alahdab, Fares

Mayo Clinic

Hepatology | November 13, 2015 | Volume: 63 | Issue: 1 | Pages: 284-306

10.1002/hep.28280 | PMID 26566246 Get It

Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped. The American Association for the Study of Liver Diseases HBV guideline methodology and writing committees developed a protocol a priori for this systematic review. We searched multiple databases for randomized controlled trials and controlled observational studies that enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral therapy. Data extraction was done by pairs of independent reviewers. We included 73 studies, of which 59 (15 randomized controlled trials and 44 observational studies) reported clinical outcomes. Moderate‐quality evidence supported the effectiveness of antiviral therapy in patients with immune active chronic HBV infection in reducing the risk of cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In immune tolerant patients, moderate‐quality evidence supports improved intermediate outcomes with antiviral therapy. Only very low‐quality evidence informed the questions about discontinuing versus continuing antiviral therapy in hepatitis B e antigen‐positive patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and about the safety of entecavir versus tenofovir. Noncomparative and indirect evidence was available for questions about stopping versus continuing antiviral therapy in hepatitis B e antigen‐negative patients, monotherapy versus adding a second agent in patients with persistent viremia during treatment, and the effectiveness of antivirals in compensated cirrhosis with low‐level viremia. Conclusion: Most of the current literature focuses on the immune active phases of chronic HBV infection; decision‐making in other commonly encountered and challenging clinical settings depends on indirect evidence. (H epatology 2016;63:284–306)
Sex Steroids Influence Brain-Derived Neurotropic Factor Secretion From Human Airway Smooth Muscle Cells
Wang, Sheng-Yu, Freeman, Michelle, Sathish, Venkatachalem , Prakash, Y. S. , Freeman, Michelle R, Wang, Sheng-Yu, Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Sathish, Venkatachalem

Mayo Clinic

Journal of Cellular Physiology | November 13, 2015 | Volume: 231 | Issue: 7 | Pages: 1586-1592

10.1002/jcp.25254 | PMID 26566264 Get It

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women
Leal, Alexis D. , Thompson, Carrie A. , Wang, Alice H., Vierkant, Robert A. , Ross, Julie A. , Virnig, Beth A , Habermann, Thomas M. , Mesa, Ruben A. , Cerhan, James R. , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 13, 2015 | Volume: 25 | Issue: 1 | Pages: 151-157

10.1158/1055-9965.epi-15-0613 | PMID 26564251 Get It

AbstractBackground: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown.Methods: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression.Results: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19–2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34–0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11–2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12–0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations.Conclusions: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN.Impact: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes. Cancer Epidemiol Biomarkers Prev; 25(1); 151–7. ©2015 AACR.
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Yufang , Tang, Nan , Thompson, Reid C., Mobley, Bret C. , Clark, Steven W., Wang, Jialiang , Sarkaria, Jann N.

Mayo Clinic

Clinical Cancer Research | November 11, 2015 | Volume: 22 | Issue: 7 | Pages: 1767-1776

10.1158/1078-0432.ccr-15-1677 | PMID 26561558 Get It

Abstract Purpose: Aberrant activation of EGFR is a hallmark of glioblastoma. However, EGFR inhibitors exhibit at best modest efficacy in glioblastoma. This is in sharp contrast with the observations in EGFR-mutant lung cancer. We examined whether activation of functionally redundant receptor tyrosine kinases (RTKs) conferred resistance to EGFR inhibitors in glioblastoma. Experimental Design: We collected a panel of patient-derived glioblastoma xenograft (PDX) lines that maintained expression of wild-type or mutant EGFR in serial xenotransplantation and tissue cultures. Using this physiologically relevant platform, we tested the abilities of several RTK ligands to protect glioblastoma cells against an EGFR inhibitor, gefitinib. Based on the screening results, we further developed a combination therapy cotargeting EGFR and insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF1R). Results: Insulin and IGF1 induced significant protection against gefitinib in the majority of EGFR-dependent PDX lines with one exception that did not express InsR or IGF1R. Blockade of the InsR/IGF1R pathway synergistically improved sensitivity to gefitinib or dacomitinib. Gefitinib alone effectively attenuated EGFR activities and the downstream MEK/ERK pathway. However, repression of AKT and induction of apoptosis required concurrent inhibition of both EGFR and InsR/IGF1R. A combination of gefitinib and OSI-906, a dual InsR/IGF1R inhibitor, was more effective than either agent alone to treat subcutaneous glioblastoma xenograft tumors. Conclusions: Our results suggest that activation of the InsR/IGF1R pathway confers resistance to EGFR inhibitors in EGFR-dependent glioblastoma through AKT regulation. Concurrent blockade of these two pathways holds promise to treat EGFR-dependent glioblastoma. Clin Cancer Res; 22(7); 1767–76. ©2015 AACR.